Page 6 - ஆராய்ச்சியாளர்கள் இல் ஆக்ஸ்ஃபர்ட் பல்கலைக்கழகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Jul 21, 2021 CHICAGO – Scientists are working on a benchmark for COVID-19 vaccine efficacy that would allow drugmakers to conduct smaller, speedier human trials to get them to market and address a huge global vaccine shortage. Researchers are trying to determine just what level of COVID-19 antibodies a vaccine must produce to provide protection against the illness. Regulators already use such benchmarks known as correlates of protection to evaluate flu vaccines without requiring large, lengthy clinical trials. “You could use it to predict efficacy from a vaccine, which will be more important as we are less able to conduct placebo-controlled trials,” said Stanley Plotkin, inventor of the Rubella vaccine and an expert on correlates of protection.

New yorkUnited statesUnited kingdomStefano collocaMarion gruberStanley plotkinPeter gilbertReithera srlFlorian krammerDrug administrationResearchers at oxford universityTaiwan medigen vaccine biologics corpIcahn school of medicine at mount sinaiOxford universityFred hutchinson cancer research centerIcahn school